ValuEngine upgraded shares of Zosano Pharma Corporation (NASDAQ:ZSAN) from a strong sell rating to a sell rating in a report published on Friday.

Shares of Zosano Pharma Corporation (NASDAQ ZSAN) opened at 0.9278 on Friday. Zosano Pharma Corporation has a 12 month low of $0.45 and a 12 month high of $3.54. The firm’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.54. The firm’s market capitalization is $36.40 million.

Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. During the same quarter in the prior year, the business posted ($0.54) EPS. Analysts anticipate that Zosano Pharma Corporation will post ($0.79) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/04/zosano-pharma-corporation-zsan-upgraded-at-valuengine.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its stake in Zosano Pharma Corporation by 591.4% in the second quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 67,774 shares during the period. Granite Point Capital Management L.P. acquired a new position in Zosano Pharma Corporation in the first quarter valued at $285,000. Victory Capital Management Inc. acquired a new position in Zosano Pharma Corporation in the first quarter valued at $449,000. Nexthera Capital LP acquired a new position in Zosano Pharma Corporation in the first quarter valued at $950,000. Finally, Perceptive Advisors LLC acquired a new position in Zosano Pharma Corporation in the first quarter valued at $950,000. Institutional investors own 22.66% of the company’s stock.

About Zosano Pharma Corporation

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.